Our results revealed that a knockdown of SATB1 in highly aggressive glioma U251 cells could alter the expression of c-Met, SLC22A18, caspase-3 and bcl-2 protein, reversing tumorigenesis, inhibiting tumor growth, invasion and angiogenesis, and inducing apoptosis. The gene discussed is BCL2; the disease is neoplasm.